Joaquin Seras Franzoso I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB). Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Joaquin Seras Franzoso LinkedIn Twitter Orcid Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).
I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles. I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy. I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.
Líneas de investigación Estudi de les bases moleculars i cel·lulars del càncer IP: Joaquin Seras Franzoso Proyectos CancerScan: Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology IP: Santiago Ramon y Cajal Agüeras Colaboradores: Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Marc Miquel Moltó Abad, Gisela Espriu Aguado, Sonia Borao Arriazu Entidad financiadora: EUROPEAN COMMISSION Financiación: 609600 Referencia: CANCERSCAN_RAMON Y CAJAL_EC/PATHFINDER_OPEN2024 Duración: 01/08/2025 - 31/07/2028 EXPAND-EV: EXPANDing the value of Extracellular Vesicles as carriers of biomarker and therapy in precision healhcare IP: Joaquin Seras Franzoso Colaboradores: - Entidad financiadora: EUROPEAN COMMISSION Financiación: 82800 Referencia: EXPAND-EV/EC/MSCA-SE/2024/SERAS Duración: 01/01/2025 - 31/12/2028 Impact of stem-related tumor extracellular vesicles subsets in TNBC progression. IP: Joaquin Seras Franzoso Colaboradores: Maria Fidel Lledò, Miriam Izquierdo Sans Entidad financiadora: Instituto de Salud Carlos III Financiación: 119567 Referencia: FI23/00223 Duración: 15/01/2024 - 14/01/2028 MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer IP: - Colaboradores: Joaquin Seras Franzoso, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN Financiación: 333099 Referencia: CPP2022-009780 Duración: 01/07/2023 - 30/06/2026 Paginación Página actual 1 Página 2 Página 3 Página 4 Siguiente página › Última página »
